Drug delivery devices and methods of making and using same
The disclosure provides drug delivery devices and methods of making and using the drug delivery devices. The devices include single and multi-layer polymer films made by a breath figure technique having therapeutic agents associated therewith. For example, the devices may be a dual layer polymer film wherein the first layer includes a therapeutic agent incorporated into it by spin coating the first agent with a polymer solution and the second agent is incorporated into the second layer by loading the agent into pores of the second layer after it is spin coated onto the first layer. In some cases one layer provides a burst release and the second layer provides a slow release drug delivery profile. The devices may take on the form of a surgical mesh with a slow release therapeutic drug.
1. A drug delivery device consisting of a multi-layer film, wherein the multi-layer film comprises: at least a first layer comprising a first therapeutic agent associated with a first biodegradable polymer film; and, at least a second layer comprising a second therapeutic agent associated with a second biodegradable polymer film, wherein the first layer of the drug delivery system is configured to provide a sustained release of the first therapeutic agent and the second layer of the drug delivery system is configured to provide a burst release of the second therapeutic agent on contact with aqueous humor; and further wherein the first therapeutic agent is 5-Flurouracil (“5-FU”); the second therapeutic agent is Mitomyacin C (“MMC”); the first and the second biodegradable polymer film comprise poly lactic-co-glycolic acid (“PLGA”); the multi-layer film is a dual-layer film; and, the first layer is formed by spin-coating 5-FU dissolved into a PLGA solution and the second layer is formed by loading MMC into the pores of an already prepared second biodegradable PLGA film.
2. A drug delivery device according to claim 1 , wherein the 5-FU is released over a period of at least 30 days, and the MMC is released in a period of about 24 hours.
3. A drug delivery device according to claim 2 , wherein sustained release of the 5-FU begins after about 24 hours.
4. A drug delivery device according to claim 3 , wherein sustained release of the 5-FU begins after about 3-5 days.
5. A drug delivery device according to claim 1 , wherein the first biodegradable polymer film and the second biodegradable polymer film degrade within about 3 months after contact with aqueous humor.
6. A drug delivery device according to claim 1 , wherein at least the first biodegradable polymer film further comprises a polyethyleneglycol (“PEG”), wherein the PLGA and the PEG are present in the at least first biodegradable polymer film in a ratio of about 1:9.
7. A drug delivery device according to claim 1 , wherein upon contact with aqueous humor during glaucoma surgery, the first film layer decreases fibroblast activity for up to about four weeks, and the second film layer decreases immediate post-operative wound healing response.
8. A drug delivery device according to claim 7 , wherein the first and the second film layer degrade in about 30-60 days.
9. A method of making the drug delivery device according to claim 1 , comprising: producing a PLGA film layer comprising 5-FU using a breath figure technique, wherein producing the PLGA film layer comprises dissolving PLGA in a solvent to form a solution and spin coating the PLGA solution along with the 5-FU in a humid environment to form a first PLGA film layer; casting a second PLGA film layer on top of the first PLGA film layer; and loading MCC into pores of the second PLGA film layer.
10. A method of treating glaucoma, comprising implanting a drug delivery device according to claim 1 in a subconjunctival space of a patient.